Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
FDA Prioritizes Reviews Of Opioid Overdose ANDAs
Jul 10 2019
•
By
Aidan Fry
Narcan is among the reference brands for which the FDA is accelerating ANDA review • Source: Shutterstock
More from Regulation
More from Policy & Regulation